Boehringer Ingelheim and 3T Biosciences enter into a second partnership to develop next-generation cancer immunotherapies

INGELHEIM, Germany and SOUTH SAN FRANCISCO, Calif., Jan. 4, 2024 /PRNewswire/ — Boehringer Ingelheim and 3T Biosciences (“3T”) today announced they have entered into a new strategic collaboration and licensing agreement focused on discovering and developing next-generation life-changing…

Click here to view original post